Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: A French retrospective study

Rheumatology

Volumn 49, Issue 9, 2010, Pages 1694-1698

  Dallocchio, Aymeric ^a   Canioni, Danièle ^a   Ruemmele, Frank ^a   Duquesne, Agnès ^b   Scoazec, Jean Yves ^b   Bouvier, Raymonde ^b   Paraf, François ^c   Languepin, Jeanne ^d   Wouters, Carine H ^a,e   Guillot, Marcel ^f   Quartier, Pierre ^a   Bader Meunier, Brigitte ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b HOSPICES CIVILS DE LYON   (France)

^c DUPUYTREN UNIVERSITY HOSPITAL   (France)

^d Hopital de la Mere et de l'Enfant   (France)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f Hôpital René Bisson   (France)

Author keywords

Crohn's disease; Etanercept; Inflammatory bowel disease; Juvenile idiopathic arthritis

Indexed keywords

CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE;

ABDOMINAL PAIN; ANOREXIA; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; COLITIS; CROHN DISEASE; DIARRHEA; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTERITIS; FEMALE; FRANCE; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFANT; INTESTINE BIOPSY; JUVENILE RHEUMATOID ARTHRITIS; MALE; MOUTH ULCER; PERIANAL ABSCESS; PRESCHOOL CHILD; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT DURATION;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; FEMALE; FRANCE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; QUESTIONNAIRES; RETROSPECTIVE STUDIES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77955738020     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq136     Document Type: Article

References (20)

1. Ramos-Casals M, Brito-Zerón P, Muñoz S et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine 2007;86:242-51.
2. Quartier P, Taupin P, Bourdeaut F et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003;48: 1093-101.
3. Lovell DJ, Reiff A, Ilowite NT et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008;58:1496-504.
4. Horneff G, De Bock F, Foeldvari et al. Safety and efficacy of combination of etanercept and methotrexate compared with etanercept only in patients with idiopathic arthritis. Preliminary data from the German etanercept registry for treatment of juvenile. Ann Rheum Dis 2009;68: 519-25.
5. Gerloni V, Pontikaki I, Gattinara M, Fantini F. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Ann Rheum Dis 2008;67:1145-52.
6. Fouache D, Goëb V, Massy-Guillemant N et al. Paradoxical adverse events of anti-tumour necrosis therapy for spondylarthropathies: a retrospective study. Rheumatol 2009;48:761-4.
7. Wiegering V, Morbach H, Dick A, Girschick HJ. Crohn's disease during etanercept therapy in juvenile idiopathic arthritis: a case report and review of the literature. Rheumatol Int 2009;30:801-4.
8. Ruemmele FM, Prieur AM, Talbotec C, Goulet O, Schmitz J. Development of Crohn disease during anti-TNF-alpha therapy in a child with juvenile idiopathic arthritis. J Pediatr Gastroenterol Nutr 2004;39:203-6.
9. Yazisiz V, Avci AB, Erbasan F, Yildirim B, Terzioǧlu E. Development of Crohn's disease following anti-tumour necrosis factor therapy (etanercept). Colorectal Dis 2008; 10:953-4.
10. Haraoui B, Krelenbaum M. Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action. Semin Arthritis Rheum 2008;39:176-81.
11. Prescott K, Costner M, Cohen S, Kazi S. Tumor necrosis factor-alpha inhibitor associated ulcerative colitis. Am J Med Sci 2007;333:137-9.
12. Braun J, Baraliakos X, Listing J et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 2007;57:639-47.
13. Petty RE, Southwood TR, Manners P et al. International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2.
14. Montgommery EA. Colon inflammatory. In: Montgommery EA, ed. Biopsy interpretation of the gastrointestinal tract. Philadelphia: Linppincott Williams and Wilkins, 2006:213-67.
15. Auvin S, Molinié F, Gower-Rousseau C et al. Incidence, clinical presentation and location at diagnosis of pediatric inflammatory bowel disease: a prospective population-based study in northern of France (1988-1999). J Pediatr Gastroenterol Nutr 2005;41: 49-55.
16. Sýkora J, Huml M, Siala K, Lád V, Pomahacová R. Fistulizing anorectal Crohn disease in a child with severe HLA-B27-associated enthesitis-related arthritis. J Pediatr Gastroenterol Nutr 2009;48:491-4.
17. Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 1998;42: 387-91.
18. Valesini G, Iannuccelli C, Marocchi E, Pascoli L, Scalzi V, Di Franco M. Biological and clinical effects of anti-TNFa treatment. Autoimmunity Rev 2007;7:35-41.
19. Harrison MJ, Dixon WG, Watson KD et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumor necrosis factor a therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2008;68:209-15.
20. Smith AM, Rahman FZ, Hayee B et al. Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease. J Exp Med 2009;206:1883-97.